Active

Contract Opportunity

Date exteneded due to holiday.

NOTICE OF INTENT TO AWARD SOLE SOURCE

The United State Army Medical Research Acquisition activity intends to award on a sole source basis, IWA FAR 13.5., with sole proprietor, Diana Caridha, Gaithersburg, MD 20878.

The Experimental Therapeutics Branch at the Walter Reed Army Institute of Research (WRAIR) The mission of the ET Branch is to discover and develop new therapeutic agents to protect military members from death, disease, and injury. The ET Branch is the nation’s primary developer of new therapeutics to prevent and/or treat infectious disease threats such as malaria, leishmaniasis, bacteria, and viruses. Collectively, ET engages in drug discovery, drug safety, drug efficacy, pharmacokinetics, and mechanism evaluation, to support preclinical and clinical therapeutic development.

The purpose of this requirement is to provide non-personal specialized expertise and support services necessary to perform l secure the provisions necessary to meet the government objectives to sustain and conduct the all-animal models used for assessing the in vivo drug efficacy, safety (tolerability), and pharmacokinetic profiles of potential therapeutics.

Objectives:

This requirement is for specialized services to develop drug screens, test drug candidates, formulate and execute protocols, and analyze data for a host of diseases and biological threats. The contractor shall adhere to all applicable standard operating procedures (SOPs), technical manuals, and laboratory safety in the performance of the following activities:

Tasks include:

3.1. Assist in the development of the next generation of therapeutics, to include (but not be limited to) anti-malarial, anti-leishmanial, anti-bacterial, and anti-viral drugs.

3.2. Collaborate with Principal Investigators to develop, coordinate, and execute the in vivo drug efficacy, safety (tolerability), and pharmacokinetic models of the Experimental Therapeutics Branch.

3.3. Manage a highly skilled team to sustain and conduct the all-animal models used for assessing the in vivo drug efficacy, safety (tolerability), and pharmacokinetic profiles of potential therapeutics.

3.4. Support all related cooperative agreements such as Material Transfer Agreements (MTA), Cooperative Research and Development Agreements (CRADA) to support internal and external grants.

3.5. Act as a Subject Matter Expert (SME) for In Vivo Imaging System (IVIS) Facility and the in vivo assays that require use of the in vivo imaging technology.

3.6. Facilitate data analysis and archiving in the in-house information and inventory system.

3.7. Generate technical reports for all animal models for the purposes of internal and external reporting and publication.

3.8 Must have up to date and approved protocols with the Institutional Animal Care and Use Committee (IACUC) so research milestones are maintained.

THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE QUOTATIONS. Responsible, interested parties may identify their interest by submitting capability information, in writing, by 12:00 p.m. EST, Friday, 10 November 2023 to Ms. Brenda Mena at brenda.i.mena.civ@health.mil . Supporting evidence must be furnished in sufficient detail to demonstrate the firm’s ability to provide the stated capability.

Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, USAMRAA will proceed with the sole source contract.

Attachments/Links